Adaptive Bio (ADPT) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ADPT Stock Forecast


Adaptive Bio stock forecast is as follows: an average price target of $12.33 (represents a 134.41% upside from ADPT’s last price of $5.26) and a rating consensus of 'Hold', based on 12 wall street analysts offering a 1-year stock forecast.

ADPT Price Target


The average price target for Adaptive Bio (ADPT) is $12.33 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $5.00. This represents a potential 134.41% upside from ADPT's last price of $5.26.

ADPT Analyst Ratings


Hold

According to 12 Wall Street analysts, Adaptive Bio's rating consensus is 'Hold'. The analyst rating breakdown for ADPT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (33.33%), 7 'Hold' (58.33%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

Adaptive Bio Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 04, 2024Mark MassaroBTIG$5.00$2.6886.57%-4.94%
Dec 21, 2022David WestenbergPiper Sandler$14.00$7.0997.46%166.16%
Aug 17, 2022David WestenbergPiper Sandler$12.00$11.553.90%128.14%
Jun 13, 2022David WestenbergPiper Sandler$7.50$6.977.60%42.59%
May 06, 2022-Morgan Stanley$18.00$8.15120.86%242.21%
Row per page
Go to

The latest Adaptive Bio stock forecast, released on Apr 04, 2024 by Mark Massaro from BTIG, set a price target of $5.00, which represents a 86.57% increase from the stock price at the time of the forecast ($2.68), and a -4.94% decrease from ADPT last price ($5.26).

Adaptive Bio Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$5.00
Last Closing Price$5.26$5.26$5.26
Upside/Downside-100.00%-100.00%-4.94%

In the current month, the average price target of Adaptive Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adaptive Bio's last price of $5.26. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 02, 2024BTIGBuyBuyHold
Apr 04, 2024BTIGBuyBuyHold
Jan 05, 2023Scotiabank-Sector OutperformInitialise
Dec 21, 2022Piper SandlerNeutralOverweightUpgrade
Dec 21, 2022BMO Capital-Market PerformDowngrade
Dec 21, 2022Citigroup-NeutralInitialise
Dec 21, 2022Barclays-Equal-WeightInitialise
Dec 21, 2022Roth Capital-BuyInitialise
Dec 21, 2022Jefferies-BuyInitialise
Dec 21, 2022SMBC Nikko-NeutralInitialise
Row per page
Go to

Adaptive Bio's last stock rating was published by BTIG on Oct 02, 2024. The company gave ADPT a "Buy" rating, the same as its previous rate.

Adaptive Bio Financial Forecast


Adaptive Bio Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$45.78M$37.92M$48.93M$37.65M$55.20M$47.83M$43.66M$38.62M$37.93M$39.47M$38.51M$38.44M$30.18M$26.30M$20.99M$20.91M$24.21M$26.06M
Avg Forecast$69.11M$59.30M$62.03M$56.72M$57.97M$50.87M$51.27M$46.73M$46.57M$40.24M$38.63M$38.78M$48.45M$42.96M$44.87M$36.81M$54.72M$47.81M$41.81M$37.77M$36.37M$36.63M$31.27M$27.72M$26.89M$23.59M$18.80M$22.34M$21.71M$22.10M
High Forecast$69.11M$59.30M$62.03M$56.72M$57.97M$50.87M$51.27M$46.73M$46.57M$40.86M$38.63M$38.78M$58.93M$47.00M$44.87M$36.81M$54.72M$47.81M$41.81M$37.77M$36.37M$36.63M$31.27M$27.72M$26.89M$23.59M$18.80M$22.34M$21.71M$22.10M
Low Forecast$69.11M$59.30M$62.03M$56.72M$57.97M$50.87M$51.27M$46.73M$46.57M$39.97M$38.63M$38.78M$44.15M$40.90M$44.87M$36.81M$54.72M$47.81M$41.81M$37.77M$36.37M$36.63M$31.27M$27.72M$26.89M$23.59M$18.80M$22.34M$21.71M$22.10M
# Analysts333344443634585443435454545443
Surprise %------------0.94%0.88%1.09%1.02%1.01%1.00%1.04%1.02%1.04%1.08%1.23%1.39%1.12%1.11%1.12%0.94%1.11%1.18%

Adaptive Bio's average Quarter revenue forecast for Mar 24 based on 4 analysts is $38.78M, with a low forecast of $38.78M, and a high forecast of $38.78M. ADPT's average Quarter revenue forecast represents a -15.31% decrease compared to the company's last Quarter revenue of $45.78M (Dec 23).

Adaptive Bio EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts333344443634585443435454545443
EBITDA------------$-40.25M$-50.96M$-47.82M$-48.75M$-36.16M$-39.28M$-47.31M$-58.01M$-56.49M$-52.47M$-46.40M$-37.97M$-41.10M$-33.89M$-33.02M$-29.75M$-18.54M$-11.89M
Avg Forecast$-67.75M$-58.14M$-60.81M$-55.60M$-56.83M$-49.87M$-50.26M$-45.81M$-45.65M$-39.44M$-37.87M$-72.56M$-47.50M$-42.11M$-43.99M$-65.96M$-62.14M$-46.87M$-40.99M$-59.97M$-35.65M$-35.91M$-30.65M$-49.08M$-26.36M$-23.13M$-18.43M$-22.31M$-21.29M$-21.66M
High Forecast$-67.75M$-58.14M$-60.81M$-55.60M$-56.83M$-49.87M$-50.26M$-45.81M$-45.65M$-39.18M$-37.87M$-58.05M$-43.28M$-40.10M$-43.99M$-52.77M$-49.71M$-46.87M$-40.99M$-47.97M$-35.65M$-35.91M$-30.65M$-39.27M$-26.36M$-23.13M$-18.43M$-17.85M$-21.29M$-21.66M
Low Forecast$-67.75M$-58.14M$-60.81M$-55.60M$-56.83M$-49.87M$-50.26M$-45.81M$-45.65M$-40.06M$-37.87M$-87.07M$-57.77M$-46.08M$-43.99M$-79.16M$-74.57M$-46.87M$-40.99M$-71.96M$-35.65M$-35.91M$-30.65M$-58.90M$-26.36M$-23.13M$-18.43M$-26.77M$-21.29M$-21.66M
Surprise %------------0.85%1.21%1.09%0.74%0.58%0.84%1.15%0.97%1.58%1.46%1.51%0.77%1.56%1.47%1.79%1.33%0.87%0.55%

undefined analysts predict ADPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Adaptive Bio's previous annual EBITDA (undefined) of $NaN.

Adaptive Bio Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts333344443634585443435454545443
Net Income------------$-69.44M$-50.30M$-47.81M$-61.74M$-24.52M$-45.17M$-51.63M$-62.52M$-61.34M$-56.00M$-49.30M$-40.64M$-44.57M$-36.72M$-33.53M$-31.40M$-20.61M$-13.95M
Avg Forecast$-28.01M$-32.02M$-29.59M$-35.95M$-35.14M$-37.98M$-38.03M$-42.68M$-42.61M$-42.39M$-49.25M$-79.29M$-48.84M$-49.92M$-51.13M$-72.08M$-67.47M$-53.51M$-63.14M$-65.53M$-66.64M$-62.10M$-61.22M$-52.54M$-43.25M$-41.46M$-41.52M$-23.55M$-29.17M$-36.56M
High Forecast$-28.01M$-32.02M$-29.59M$-35.95M$-35.14M$-37.98M$-38.03M$-42.68M$-42.61M$-38.15M$-49.25M$-63.43M$-45.79M$-33.77M$-51.13M$-57.66M$-53.98M$-53.51M$-63.14M$-52.42M$-66.64M$-62.10M$-61.22M$-42.03M$-43.25M$-41.46M$-41.52M$-18.84M$-29.17M$-36.56M
Low Forecast$-28.01M$-32.02M$-29.59M$-35.95M$-35.14M$-37.98M$-38.03M$-42.68M$-42.61M$-49.45M$-49.25M$-95.14M$-53.42M$-54.33M$-51.13M$-86.49M$-80.97M$-53.51M$-63.14M$-78.63M$-66.64M$-62.10M$-61.22M$-63.04M$-43.25M$-41.46M$-41.52M$-28.26M$-29.17M$-36.56M
Surprise %------------1.42%1.01%0.94%0.86%0.36%0.84%0.82%0.95%0.92%0.90%0.81%0.77%1.03%0.89%0.81%1.33%0.71%0.38%

Adaptive Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Adaptive Bio SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts333344443634585443435454545443
SG&A------------$42.63M$40.57M$46.17M$43.14M$46.14M$42.27M$45.48M$50.24M$50.04M$45.10M$39.28M$35.54M$31.94M$26.55M$26.57M$25.83M$20.83M$17.58M
Avg Forecast$69.72M$59.82M$62.58M$57.22M$58.48M$51.32M$51.72M$47.14M$46.97M$40.59M$38.97M$39.12M$48.88M$43.34M$45.27M$37.13M$55.20M$48.23M$42.17M$38.10M$36.69M$36.95M$31.54M$27.96M$27.12M$23.80M$18.96M$19.37M$21.90M$22.29M
High Forecast$69.72M$59.82M$62.58M$57.22M$58.48M$51.32M$51.72M$47.14M$46.97M$41.22M$38.97M$39.12M$59.45M$47.41M$45.27M$37.13M$55.20M$48.23M$42.17M$38.10M$36.69M$36.95M$31.54M$27.96M$27.12M$23.80M$18.96M$23.25M$21.90M$22.29M
Low Forecast$69.72M$59.82M$62.58M$57.22M$58.48M$51.32M$51.72M$47.14M$46.97M$40.32M$38.97M$39.12M$44.54M$41.26M$45.27M$37.13M$55.20M$48.23M$42.17M$38.10M$36.69M$36.95M$31.54M$27.96M$27.12M$23.80M$18.96M$15.50M$21.90M$22.29M
Surprise %------------0.87%0.94%1.02%1.16%0.84%0.88%1.08%1.32%1.36%1.22%1.25%1.27%1.18%1.12%1.40%1.33%0.95%0.79%

Adaptive Bio's average Quarter SG&A projection for Mar 24 is $39.12M, based on 4 Wall Street analysts, with a range of $39.12M to $39.12M. The forecast indicates a -8.25% fall compared to ADPT last annual SG&A of $42.63M (Dec 23).

Adaptive Bio EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts333344443634585443435454545443
EPS------------$-0.48$-0.35$-0.33$-0.43$-0.17$-0.32$-0.36$-0.44$-0.43$-0.40$-0.35$-0.29$-0.33$-0.27$-0.26$-0.25$-0.17$-0.11
Avg Forecast$-0.19$-0.22$-0.20$-0.24$-0.24$-0.26$-0.26$-0.29$-0.29$-0.29$-0.33$-0.35$-0.33$-0.34$-0.35$-0.38$-0.35$-0.36$-0.43$-0.45$-0.45$-0.42$-0.42$-0.40$-0.29$-0.28$-0.28$-0.21$-0.20$-0.25
High Forecast$-0.19$-0.22$-0.20$-0.24$-0.24$-0.26$-0.26$-0.29$-0.29$-0.26$-0.33$-0.35$-0.31$-0.23$-0.35$-0.38$-0.35$-0.36$-0.43$-0.45$-0.45$-0.42$-0.42$-0.40$-0.29$-0.28$-0.28$-0.21$-0.20$-0.25
Low Forecast$-0.19$-0.22$-0.20$-0.24$-0.24$-0.26$-0.26$-0.29$-0.29$-0.34$-0.33$-0.35$-0.36$-0.37$-0.35$-0.38$-0.35$-0.36$-0.43$-0.45$-0.45$-0.42$-0.42$-0.40$-0.29$-0.28$-0.28$-0.21$-0.20$-0.25
Surprise %------------1.45%1.03%0.95%1.14%0.49%0.88%0.84%0.97%0.95%0.95%0.84%0.72%1.12%0.96%0.92%1.20%0.86%0.44%

According to undefined Wall Street analysts, Adaptive Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADPT previous annual EPS of $NaN (undefined).

Adaptive Bio Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.63$70.0011011.11%Buy
ELEVElevation Oncology$0.52$9.001630.77%Buy
KNTEKinnate Biopharma$2.65$30.001032.08%Hold
VERVVerve Therapeutics$6.05$21.50255.37%Buy
SANASana Bio$3.76$12.00219.15%Buy
VIRVir Bio$9.37$26.60183.88%Buy
APLSApellis Pharmaceuticals$28.56$76.13166.56%Buy
BEAMBeam Therapeutics$24.36$64.20163.55%Buy
ADPTAdaptive Bio$5.26$12.33134.41%Hold
LEGNLegend Biotech$43.61$82.6289.45%Buy
RPRXRoyalty Pharma$27.20$43.3359.30%Buy
CRBUCaribou Biosciences$2.34$3.0028.21%Buy
ZURAZura Bio$4.37$5.0014.42%Buy
KRYSKrystal Biotech$170.85$191.0011.79%Buy
VECTVectivBio$16.87$18.006.70%Buy
RPHMReneo Pharmaceuticals$18.20$18.00-1.10%Buy
IKNAIkena Oncology$1.72$1.33-22.67%Buy

ADPT Forecast FAQ


No, according to 12 Wall Street analysts, Adaptive Bio (ADPT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 33.33% of ADPT's total ratings.

Adaptive Bio (ADPT) average price target is $12.33 with a range of $5 to $18, implying a 134.41% from its last price of $5.26. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ADPT stock, the company can go up by 134.41% (from the last price of $5.26 to the average price target of $12.33), up by 242.21% based on the highest stock price target, and down by -4.94% based on the lowest stock price target.

ADPT's average twelve months analyst stock price target of $12.33 supports the claim that Adaptive Bio can reach $8 in the near future.

Adaptive Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $206.85M (high $206.85M, low $206.85M), average EBITDA is $-203M (high $-203M, low $-203M), average net income is $-154M (high $-154M, low $-154M), average SG&A $208.66M (high $208.66M, low $208.66M), and average EPS is $-1.044 (high $-1.044, low $-1.044). ADPT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $247.18M (high $247.18M, low $247.18M), average EBITDA is $-242M (high $-242M, low $-242M), average net income is $-126M (high $-126M, low $-126M), average SG&A $249.34M (high $249.34M, low $249.34M), and average EPS is $-0.852 (high $-0.852, low $-0.852).

Based on Adaptive Bio's last annual report (Dec 2023), the company's revenue was $170.28M, which missed the average analysts forecast of $173.1M by -1.63%. Apple's EBITDA was $-179M, missing the average prediction of $-200M by -10.12%. The company's net income was $-225M, beating the average estimation of $-222M by 1.48%. Apple's SG&A was $172.51M, missing the average forecast of $174.61M by -1.20%. Lastly, the company's EPS was $-1.56, beating the average prediction of $-1.394 by 11.92%. In terms of the last quarterly report (Dec 2023), Adaptive Bio's revenue was $45.78M, missing the average analysts' forecast of $48.45M by -5.51%. The company's EBITDA was $-40.247M, missing the average prediction of $-47.498M by -15.27%. Adaptive Bio's net income was $-69.441M, beating the average estimation of $-48.84M by 42.18%. The company's SG&A was $42.63M, missing the average forecast of $48.88M by -12.77%. Lastly, the company's EPS was $-0.48, beating the average prediction of $-0.331 by 44.88%